NURS 6521 / NURS6521 Advanced Pharmacology Midterm
Exam Question Bank (Latest 2026/2027 Edition) – Questions,
Answers & Detailed Rationales
──────────────────────────────
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–Q5)
──────────────────────────────
Question 1
A 68-year-old patient with heart failure is prescribed oral digoxin 0.25 mg daily. The
prescriber notes that the patient has moderate renal impairment (CrCl 40 mL/min) and
decides to use a loading dose. Which pharmacokinetic principle best explains why a
loading dose is necessary when initiating digoxin therapy?
A. To bypass first-pass metabolism in the liver
B. To achieve steady-state concentration more rapidly
C. To increase the volume of distribution in tissues
D. To decrease the drug's protein binding affinity
Correct Answer: B
Rationale:
A loading dose is administered to achieve therapeutic plasma concentrations more
quickly than waiting for accumulation through repeated maintenance doses alone.
Digoxin has a long half-life (36–48 hours in patients with normal renal function, longer
in renal impairment), so steady state would take approximately 5–7 half-lives (7–14
days) without a loading dose. The loading dose is calculated based on volume of
distribution, not to bypass first-pass metabolism, alter protein binding, or change Vd.
Question 2
,A 55-year-old patient with chronic kidney disease (CrCl 25 mL/min) is prescribed
gentamicin for a severe gram-negative infection. The pharmacist calculates an
extended-interval dosing regimen (7 mg/kg every 24–48 hours) rather than traditional
multiple daily doses. Which pharmacokinetic parameter primarily supports this dosing
adjustment?
A. Increased bioavailability in renal impairment
B. Concentration-dependent bacterial killing and post-antibiotic effect
C. Decreased volume of distribution in renal failure
D. Enhanced hepatic metabolism of aminoglycosides
Correct Answer: B
Rationale:
Extended-interval aminoglycoside dosing is supported by concentration-dependent
killing (higher peak-to-MIC ratios improve efficacy) and the post-antibiotic effect, which
allows for prolonged bacterial suppression even when drug levels fall below the MIC.
This approach also reduces nephrotoxicity risk by allowing drug-free intervals for renal
recovery. Aminoglycosides are not hepatically metabolized, and renal impairment does
not significantly increase bioavailability or decrease Vd.
Question 3
A patient on warfarin therapy has an INR of 4.2 after starting amiodarone for atrial
fibrillation. The prescriber recognizes that amiodarone inhibits multiple CYP450
enzymes. Which pharmacodynamic consequence best describes the interaction
between amiodarone and warfarin?
A. Amiodarone displaces warfarin from albumin binding sites
B. Amiodarone inhibits CYP2C9 and CYP1A2, reducing S-warfarin and R-warfarin
metabolism
C. Amiodarone induces hepatic glucuronidation of warfarin
D. Amiodarone increases warfarin renal excretion
,Correct Answer: B
Rationale:
Amiodarone is a potent inhibitor of CYP2C9 (primary enzyme for S-warfarin
metabolism) and CYP1A2 and CYP3A4 (involved in R-warfarin metabolism). Inhibition
of these enzymes decreases warfarin clearance, leading to increased plasma
concentrations and elevated INR. While warfarin is highly protein-bound, amiodarone's
effect is primarily metabolic, not displacement-mediated. Amiodarone does not induce
glucuronidation or increase renal excretion of warfarin.
Question 4
A 42-year-old patient with partial agonist activity at mu-opioid receptors is prescribed
buprenorphine for opioid use disorder. The patient asks why buprenorphine is less likely
to cause respiratory depression compared to full agonists like morphine. Which
pharmacodynamic principle explains this safety advantage?
A. Buprenorphine has a higher intrinsic efficacy than morphine
B. Buprenorphine has high affinity but low intrinsic efficacy at mu-receptors, producing a
ceiling effect
C. Buprenorphine acts as a competitive antagonist at all opioid receptors
D. Buprenorphine selectively activates kappa-opioid receptors
Correct Answer: B
Rationale:
Buprenorphine is a partial agonist at mu-opioid receptors with very high receptor affinity
but lower intrinsic efficacy than full agonists like morphine. This creates a ceiling effect
for respiratory depression, making overdose less likely. Buprenorphine does not have
higher intrinsic efficacy than morphine, is not a pure antagonist, and does not selectively
activate kappa receptors (it is a partial mu-agonist and kappa-antagonist).
, Question 5
A patient receiving intravenous phenytoin for seizure prophylaxis develops hypotension
and arrhythmia during rapid administration. Which pharmacokinetic principle explains
this adverse effect?
A. Phenytoin undergoes zero-order kinetics at therapeutic concentrations
B. The propylene glycol vehicle in IV phenytoin causes cardiovascular toxicity
C. Phenytoin has high oral bioavailability causing rapid absorption
D. Phenytoin is extensively metabolized by CYP3A4 during first-pass
Correct Answer: B
Rationale:
IV phenytoin contains propylene glycol as a solubilizing vehicle, which can cause
hypotension, bradycardia, and cardiac arrhythmias when administered rapidly
(maximum rate 50 mg/min in adults, 25 mg/min in elderly). While phenytoin does
exhibit saturable (zero-order) metabolism at higher concentrations, the acute
cardiovascular effects during IV administration are attributed to the propylene glycol
vehicle, not the drug's pharmacokinetic profile or bioavailability.
──────────────────────────────
SECTION 2: PHARMACOGENOMICS (Q6–Q10)
──────────────────────────────
Question 6
A 62-year-old patient with atrial fibrillation is prescribed warfarin 5 mg daily.
Pharmacogenetic testing reveals the patient is a CYP2C9*3/*3 poor metabolizer and
VKORC1 -1639A/A (high sensitivity). Based on CPIC guidelines, what is the most
appropriate initial warfarin dose adjustment?
A. Continue 5 mg daily and monitor INR weekly
B. Reduce initial dose to 1–2 mg daily and monitor INR within 3–5 days
C. Increase dose to 7.5 mg daily due to poor metabolism requiring higher doses
Exam Question Bank (Latest 2026/2027 Edition) – Questions,
Answers & Detailed Rationales
──────────────────────────────
SECTION 1: PHARMACOKINETICS & PHARMACODYNAMICS (Q1–Q5)
──────────────────────────────
Question 1
A 68-year-old patient with heart failure is prescribed oral digoxin 0.25 mg daily. The
prescriber notes that the patient has moderate renal impairment (CrCl 40 mL/min) and
decides to use a loading dose. Which pharmacokinetic principle best explains why a
loading dose is necessary when initiating digoxin therapy?
A. To bypass first-pass metabolism in the liver
B. To achieve steady-state concentration more rapidly
C. To increase the volume of distribution in tissues
D. To decrease the drug's protein binding affinity
Correct Answer: B
Rationale:
A loading dose is administered to achieve therapeutic plasma concentrations more
quickly than waiting for accumulation through repeated maintenance doses alone.
Digoxin has a long half-life (36–48 hours in patients with normal renal function, longer
in renal impairment), so steady state would take approximately 5–7 half-lives (7–14
days) without a loading dose. The loading dose is calculated based on volume of
distribution, not to bypass first-pass metabolism, alter protein binding, or change Vd.
Question 2
,A 55-year-old patient with chronic kidney disease (CrCl 25 mL/min) is prescribed
gentamicin for a severe gram-negative infection. The pharmacist calculates an
extended-interval dosing regimen (7 mg/kg every 24–48 hours) rather than traditional
multiple daily doses. Which pharmacokinetic parameter primarily supports this dosing
adjustment?
A. Increased bioavailability in renal impairment
B. Concentration-dependent bacterial killing and post-antibiotic effect
C. Decreased volume of distribution in renal failure
D. Enhanced hepatic metabolism of aminoglycosides
Correct Answer: B
Rationale:
Extended-interval aminoglycoside dosing is supported by concentration-dependent
killing (higher peak-to-MIC ratios improve efficacy) and the post-antibiotic effect, which
allows for prolonged bacterial suppression even when drug levels fall below the MIC.
This approach also reduces nephrotoxicity risk by allowing drug-free intervals for renal
recovery. Aminoglycosides are not hepatically metabolized, and renal impairment does
not significantly increase bioavailability or decrease Vd.
Question 3
A patient on warfarin therapy has an INR of 4.2 after starting amiodarone for atrial
fibrillation. The prescriber recognizes that amiodarone inhibits multiple CYP450
enzymes. Which pharmacodynamic consequence best describes the interaction
between amiodarone and warfarin?
A. Amiodarone displaces warfarin from albumin binding sites
B. Amiodarone inhibits CYP2C9 and CYP1A2, reducing S-warfarin and R-warfarin
metabolism
C. Amiodarone induces hepatic glucuronidation of warfarin
D. Amiodarone increases warfarin renal excretion
,Correct Answer: B
Rationale:
Amiodarone is a potent inhibitor of CYP2C9 (primary enzyme for S-warfarin
metabolism) and CYP1A2 and CYP3A4 (involved in R-warfarin metabolism). Inhibition
of these enzymes decreases warfarin clearance, leading to increased plasma
concentrations and elevated INR. While warfarin is highly protein-bound, amiodarone's
effect is primarily metabolic, not displacement-mediated. Amiodarone does not induce
glucuronidation or increase renal excretion of warfarin.
Question 4
A 42-year-old patient with partial agonist activity at mu-opioid receptors is prescribed
buprenorphine for opioid use disorder. The patient asks why buprenorphine is less likely
to cause respiratory depression compared to full agonists like morphine. Which
pharmacodynamic principle explains this safety advantage?
A. Buprenorphine has a higher intrinsic efficacy than morphine
B. Buprenorphine has high affinity but low intrinsic efficacy at mu-receptors, producing a
ceiling effect
C. Buprenorphine acts as a competitive antagonist at all opioid receptors
D. Buprenorphine selectively activates kappa-opioid receptors
Correct Answer: B
Rationale:
Buprenorphine is a partial agonist at mu-opioid receptors with very high receptor affinity
but lower intrinsic efficacy than full agonists like morphine. This creates a ceiling effect
for respiratory depression, making overdose less likely. Buprenorphine does not have
higher intrinsic efficacy than morphine, is not a pure antagonist, and does not selectively
activate kappa receptors (it is a partial mu-agonist and kappa-antagonist).
, Question 5
A patient receiving intravenous phenytoin for seizure prophylaxis develops hypotension
and arrhythmia during rapid administration. Which pharmacokinetic principle explains
this adverse effect?
A. Phenytoin undergoes zero-order kinetics at therapeutic concentrations
B. The propylene glycol vehicle in IV phenytoin causes cardiovascular toxicity
C. Phenytoin has high oral bioavailability causing rapid absorption
D. Phenytoin is extensively metabolized by CYP3A4 during first-pass
Correct Answer: B
Rationale:
IV phenytoin contains propylene glycol as a solubilizing vehicle, which can cause
hypotension, bradycardia, and cardiac arrhythmias when administered rapidly
(maximum rate 50 mg/min in adults, 25 mg/min in elderly). While phenytoin does
exhibit saturable (zero-order) metabolism at higher concentrations, the acute
cardiovascular effects during IV administration are attributed to the propylene glycol
vehicle, not the drug's pharmacokinetic profile or bioavailability.
──────────────────────────────
SECTION 2: PHARMACOGENOMICS (Q6–Q10)
──────────────────────────────
Question 6
A 62-year-old patient with atrial fibrillation is prescribed warfarin 5 mg daily.
Pharmacogenetic testing reveals the patient is a CYP2C9*3/*3 poor metabolizer and
VKORC1 -1639A/A (high sensitivity). Based on CPIC guidelines, what is the most
appropriate initial warfarin dose adjustment?
A. Continue 5 mg daily and monitor INR weekly
B. Reduce initial dose to 1–2 mg daily and monitor INR within 3–5 days
C. Increase dose to 7.5 mg daily due to poor metabolism requiring higher doses
